SUMMARY There have been considerable advances in understanding the metabolic role of the endothelial lining cells of the blood vessels. Angiotensin-converting enzyme activity is concentrated in these cells, especially those lining the pulmonary circulation. The enzyme exerts control over systemic vascular tone indirectly through the powerful pressor effect of angiotensin II. A number of therapeutic agents are now available which directly inhibit converting enzyme activity and thereby effect a reduction in blood pressure.
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Macrophages are the source of increased angiotensin-converting enzyme activity commonly found in association with active sarcoidosis. A better understanding of this phenomenon may give fresh insight into this puzzling condition. Pulmonary endothelial metabolism is affected by lung injury and it is likely that in this situation changing activities of serum angiotensin converting enzyme may indicate the extent of damage and the response to therapy. The full clinical significance of serum ACE measurements has yet to be established. However, raised activities have been reported in a number of other conditions and diabetes mellitus and hyperthyroidism are of particular current interest.
The numerous methods and reference ranges described in the literature for the measurement of serum ACE activity require further assessment, and there is a clear need for an accepted reference method.
Angiotensin I, a decapeptide generated by action of the enzyme renin on a glycoprotein substrate angiotensinogen, is converted to the pressor octapeptide angiotensin II. The exopeptidase responsible for this conversion was first identified and isolated in plasma by Skeggs et al, ' 2 who named it angiotensinconverting enzyme. This enzyme is a halideactivated, EDTA-sensitive, peptidase that catalyses the cleavage of dipeptidyl residues from the COOH termini of peptide substrates,3 and releases His-Leu from the COOH terminus of the decapeptide angiotensin I.
The ready conversion of angiotensin I to angiotensin II was assumed to take place in the circulation until Ng and Vane4 recognised that the enzyme activity present in plasma was insufficient to account for the rapidity of "in vivo" conversion, and demonstrated most conversion of circulating angiotensin I to angiotensin II occurred during passage through the lungs. Stanley and Biron' confirmed the importance *Present address: Harefield Hospital, Harefield, Middlesex.
..Accepted for publication 17 January 1983 of lung as a site of angiotensin-converting enzyme activity by demonstrating reduced angiotensin I conversion in dogs on cardiopulmonary bypass; the lowered rate of conversion, however, was still higher than that in blood alone.
The pulmonary vascular bed is uniquely placed to modify levels of circulating vasoactive substances, being immediately up stream of the high pressure systemic circulation and receiving virtually the whole cardiac output. However, the fact that blood pressure control is maintained, albeit at a lower level, during cardiopulmonary bypass indicates that angiotensinconverting enzyme is present in vascular beds other than the lungs.6 Cushman and Cheung7 measured angiotensin-converting enzyme activity in a large number of rat tissue homogenates and found high specific activities in lung and in segments of the digestive tract but the highest activities in mature animals were in the testes and epididymis associated with tubular fluids, but not in sperm cells.
Other sites in which conversion of angiotensin I to II has been reported to occur include the renal vasculature of humans8 and dogs,9-" the vascular bed of the intestine,'2 the hind limb of the dog" forearm Angiotensin-converting enzyme and its clinical significance -a review arteries and hand veins in man. '3 In 1977 Lanzillo'4 isolated angiotensin-converting enzyme from human serum and as expected, found high concentrations in the vascular bed of the lungs.
Electron microscope studies with microperoxidase labelled antibody against angiotensin-converting enzyme localise the enzyme activity to the luminal surface of the capillary endothelium and associated caveolae in the aorta, lungs, and in other vascular beds'5 and this work provided visual confirmation of the many reports linking angiotensin-converting enzyme to the vascular endothelium. 1614Therefore, angiotensin-converting enzyme is a membranebound glycoprotein located predominantly in endothelial pinocytic vesicles. Circulating angiotensinconverting enzyme almost certainly derives from sloughing of, or secretion from, the endothelium. The unique feature of the pulmonary circulation in terms of the renin-angiotensin system is that it is the only vascular bed through which angiotensin II passes without inactivation.'7 Ferreira and Vane'8 investigated bradykinin, another vasoactive substance, and found its activity disappeared during circulation through the lungs, leading Ng and Vane'9 to suggest that the same pulmonary enzyme responsible for conversion of angiotensin I may also inactivate bradykinin. Supporting evidence for this hypothesis includes finding that bradykinin is a competitive inhibitor of angiotensin I conversion and that bradykinin potentiating factors (peptides from the venom of a Brazilian pit-viper Bothrops jararaca) not only inhibit the destruction of bradykinin by plasma, but also inhibit the conversion of angiotensin I by lung extracts. 20 The isolation of snake venom inhibitors (Bothrops jararaca) of angiotensin-converting enzyme4 enabled studies to be made showing the importance of the renin-angiotensin system in the maintenance of blood pressure. A number of other inhibitors have been characterised and synthesised2-24 and shown to possess similar pharmacological properties with inhibition of the vasopressor response to angiotensin and enhancement of the vaso depressor effect of bradykinin.22 It was later established that pure converting enzyme from rabbit,25 and pig lung26 catalysed sequential release of Phe-Arg and Ser-Pro from the COOH-terminus of bradykinin.
The details of the two protease pathways that share angiotensin-converting enzyme are summarised in Fig. 1 . The one enzyme acting upon its two currently recognised substrates has been classified as a peptidyldipeptide hydrolase and named "peptidyl dipeptidase" by the IUPAC-IUB Commission on Biochemical nomenclature. Since large amounts of angiotensin I converting enzyme are found in plasma and in a number of organs and since angiotensin I infused in supraphysiological concentration is rapidly converted into angiotensin II in vivo, the conversion step has not generally been regarded as rate-limiting for angiotensin II production. Relatively little attention has been given to the regulation of converting enzyme activity in vivo.
However, several reports have suggested that alterations in angiotensin I conversion occur in pulmonary disease or when abnormalities in pulmonary function are experimentally induced. Manipulation of pulmonary vascular surface area and mean transit time through the pulmonary capillary bed, by changing pulmonary venous pressure, altered conversion of infused angiotensin I in the isolated perfused dog lung.2" Molteni28 studied changes in both serum and pulmonary angiotensin-converting enzyme activity and renal renin content in mice exposed to hypoxia in a hypobaric chamber at 0 5 atmospheres. A small fall in the activity of both enzymes was demonstrated at two days followed by a progressive rise reaching significance (p < 0-005) by nine days. The finding in dogs that acute hypoxia inhibited the activity of angiotensin-converting enzyme suggested a possible explanation for the low plasma aldosterone and raised plasma renin activity found at altitude. 29 Milledge and Catley30 studied the effect of moderate exercise continued for 120 min upon renin, aldosterone and angiotensin-converting enzyme. After 60 min exercise while breathing room air plasma renin activity and plasma aldosterone rose while angiotensin-converting enzyme activity remained unchanged. The same subjects continued exercise for another 60 min while breathing 12-8% oxygen and further blood samples showed a 30% fall in angiotensin-converting enzyme activity and a further rise in renin and aldosterone. These findings may have implications for humans who suffer from mountain sickness on exercise at altitude. Therefore, alterations in pulmonary function may have a regulatory effect on the renin-angiotensin system through the activity of angiotensin I converting enzyme.
This led to studies of the enzyme's activity in patients with pulmonary disease.3' Depressed converting enzyme activity has been reported in patients with several kinds of pulmonary disease, including chronic bronchitis and emphysema, carcinoma of the bronchus, bronchial asthma and cystic fibrosis.3 '-33 This raised the possibility that the reduction in converting enzyme activity may relate to a loss of vascular endothelial surface area; but in fact no correlation was demonstrated between the severity of the pulmonary disease and reduction in converting enzyme activity.
In contrast, Lieberman in 197532 demonstrated that serum converting enzyme activity was raised in sarcoidosis and his finding has been confirmed by many, and is discussed further. Cushman and Cheung38 described a method for assaying the enzyme's activity in rabbit lung extracts and measured the activity in terms of the rate of release of hippurate from a substrate analogue hippuryl-L-histidyl-L-leucine, which substitutes for angiotensin I. Cushman and Cheung's method as modified by Lieberman32 is simple to perform and is now widely used to measure serum ACE activity. The test serum and substrate are incubated under controlled conditions. The reaction is terminated by acidification, and after separating the unhydrolysed substrate by extraction with ethyl acetate, hippurate is measured spectrophotometrically by determining its absorbance at 228 nm. In the authors' experience the method is relatively insensitive and difficult to control when used for the routine assay of serum ACE. All traces of ethyl acetate must be removed by evaporation for this substance absorbs strongly at 228 nm and therefore interferes with the assay. Lipaemic or haemolysed serum samples may cause interference in the extraction step. Chiknas39 described a modification of Cushman and Cheung's method38 in which high pressure liquid chromatography is used to measure the hippuric acid end product. This procedure overcomes a number of problems encountered with the spectrophotometric assay.
An alternative spectrophotometric method444' uses cyanuric chloride/dioxan as reagent which reacts with liberated hippurate in the presence of phosphate buffer to yield a chromogen that is quantified by its absorbance at 382 nm. Recently, a two-point kinetic assay based on this reaction has been described,42
which is said to be unaffected by jaundiced or lipaemic specimens.
Friedland and Silverstein43 described a sensitive and reproducible fluorimetric assay using hippuryl-Lhistidyl-L-leucine as substrate in which the rate of production of L-histidyl-L-leucine is quantified spectrofluorometrically by the formation of a fluores- 
Origin ofincreased serum ACE in sarcoidosis
The origin of the increased ACE activity in sarcoidosis is debated, but is thought to reflect stimulation of the monocyte macrophage system. The high turnover sarcoid granulomas are sites of considerable macrophage activity and receive massive reinforcements of monocytes to sustain their activity.80 The epithelioid cells are derived from macrophages, appear biosynthetically active8' and are the most likely source of the increased serum and tissue ACE activity as well as 942 other biologically active molecules, including lysozyme, glucuronidase and elastase. This hypothesis is supported by the following evidence. Human and rabbit monocytes, the precursors of macrophages, can be induced on culture to secrete ACE in concentrations up to 700 times that obtained before induction.8283 Immunofluorescence studies localise angiotensin II specified fluorescence to epithelioid cells, indirectly locating abundant ACE activity84 to specific cells in sarcoid granulomas.
Diagnostic sensitivity
The reported diagnostic sensitivity of serum ACE varies; but overall some two-thirds of patients with active sarcoidosis have raised enzyme activity. An even higher proportion will show increased ACE activity in fluid aspirated from the lungs at bronchoalveolar lavage and virtually all will show increased ACE activity in biopsied granulomatous lymph nodes."59-6
Serum ACE activity is independent ofsex, race and diurnal variation in normal adult subjects (> 18 y of age) and shows no significant fluctuation throughout adult life. In normal healthy infants, children and early adolescents serum ACE activity is substantially higher and more variable than in adults32 76 77 85 and then declines to adult activities as growth ceases. Because of this variability, a normal range of serum ACE activity for patients under 18 y remains to be generally established. 67 In our series, serum ACE activity was measured in normal adult subjects (> 18 y), in adult patients with sarcoidosis and other granulomatous or respiratory diseases using the spectrofluorimetric method of Friedland and Silverstein. The normal range was from 16 to 52 nmol/min/ml with a mean of 34 nmol/min/ml (mean + 2SD = 34 ± 18), obtained from 80 age and sex matched healthy adult subjects, (mean age 42 y, range 18-60 y).
Compared to normal subjects serum ACE activity in 146 sarcoid patients was significantly raised (p < 0.001) with a mean activity of 54 + 27 nmol/min/ml (mean + SD), (Fig. 2) . Serum ACE was raised in about half with active untreated sarcoidosis and in one-fifth after corticosteroid treatment. The highest individual enzyme activities are found in those patients with extensive pulmonary and hepatic involvement. Serum ACE activity appears to be most influenced by the extent of sarcoidosis, for most investigators demonstrate a clear trend for activity to increase in parallel with the degree of radiographic or clinical abnormality. In our series this trend was very apparent, for raised serum ACE was found in 27% of sarcoidosis patients with a normal chest radiograph, in 56% with hilar gland enlargement but clear lung fields (stage 1) in 72% with pulmonary infiltration in Extrinsic allergic alveolitis 22 3 14 Leprosy (86) 95 32 34 Coccidioidomycosis (86 
